ClinicalTrials.gg
Enrolling by invitationNCT07747662Updated Oct 26, 2026

Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study

An interventional study of Adaptive Optics Scanning Light Ophthalmoscopy and Microperimetry in Geographic Atrophy, sponsored by University of Wisconsin, Madison. Enrolling by invitation at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 26, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Planned enrollment
101st of 107
10 · median 98
Started
2026
with 8 others
No phase
11 of 131
4 open now
Primary completion
2027-02
later than 8 of 44 live
Registered
129th of 131
by date

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 101st largest by planned enrollment of the 107 interventional ones that give a count, is one of 9 that started in 2026, is one of 11 with no phase, reaches primary completion later than 8 of the 44 other live ones, and was the 129th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Geographic Atrophy studies recruiting now, 32 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

This research sub-study is to evaluate if combining images from Optical Coherence Tomography (OCT) scans with Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) could show a link between structural changes in the back of the eye and vision. 10 participants that were enrolled in the COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy study [NCT05961332] will be approached to enroll. Participants may complete OCT imaging and initial assessments during an initial visit and may return for additional procedures, including microperimetry and AOSLO imaging, within a window of up to 4 weeks.

Read the detailed description

Age-related macular degeneration (AMD) is a leading cause of blindness worldwide, with geographic atrophy (GA) representing the advanced, untreatable form of the disease. GA leads to progressive degeneration of retinal cells critical for vision, resulting in irreversible vision loss and a significant impact on patients' quality of life. Despite the prevalence of GA, treatment options remain limited. Current therapeutic strategies focus on slowing the enlargement of atrophic regions, but clinical trials have faced challenges in demonstrating clear patient benefits.

In clinical practice, GA progression is often evaluated by measuring the area of atrophy on retinal imaging, such as fundus autofluorescence (FAF) and, more recently, optical coherence tomography (OCT). These structural biomarkers are used in clinical trials to assess the efficacy of new drugs, with the FDA accepting a reduction in the rate of GA enlargement as a successful outcome. However, these structural metrics often fail to correlate with functional vision loss, leaving patients and physicians disappointed by treatments that may stabilize GA progression without improving their visual outcomes.

The ellipsoid zone (EZ), a hyperreflective layer visualized on OCT, represents the structural integrity of photoreceptors-cells responsible for converting light into visual signals. In patients with one or more GA lesions, OCT imaging shows that the EZ is typically absent within the GA, while the EZ in the perilesional zone may be attenuated or damaged. Perilesional EZ loss is thought to represent the area at highest risk for future vision loss. With the FDA approval of photoreceptor preservation as an endpoint for GA trials, there has been significant interest in measuring EZ loss from OCT scans. Drug approval will now focus on the prevention of EZ loss in the perilesional areas rather than GA area expansion. However, it is important to establish whether the absence of the EZ truly indicates photoreceptor damage and whether there is a functional correlation between EZ loss and visual sensitivity. Adaptive Optics and microperimetry are two modalities that can help address this.

This sub-study is a pilot comparative imaging study. In addition to the imaging procedures collected for the main COCO GA study [NCT05961332], participants will have the following study images obtained:

  • Spectralis OCT (if applicable),
  • visual acuity,
  • ocular biometry, which is a non-invasive eye test using a machine called an IOL master,
  • microperimetry, and
  • Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO)
03

Conditions studied

  • Geographic Atrophy

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 50 years or older and may be either male or female and may be of any race
  • Established diagnosis of geographic atrophy (GA) due to age-related macular degeneration (AMD)
  • GA characteristics: GA area of between 1.25 mm² and 23 mm², with seventy percent of eyes having GA area ranging from 2.5 mm² to 17.5 mm². GA may be unifocal or multifocal. GA may be subfoveal or extrafoveal, with twenty-five percent of eyes having subfoveal GA. The presence of concurrent peripapillary atrophy will not exclude participants from participation
  • Willing to participate as evidenced by signing the written

Additional Sub-study Inclusion Criteria:

  • Early-stage GA defined as

    • GA area of between 1.25 mm2 and 23 mm2
    • GA may be unifocal or multifocal
    • GA may be subfoveal or extrafoveal
    • Concurrent peripapillary atrophy will not exclude participant from participation
    • Phakic and pseudophakic participants are eligible for enrollment, with phakic participants prioritized when feasible.

Exclusion criteria

Exclusion Criteria (from the main study):

  • Unable to tolerate ophthalmic imaging
  • Presence of neovascular AMD on optical coherence tomography (OCT) as confirmed by an ophthalmologist
  • Presence of significant media opacity preventing adequate retinal imaging
  • Presence of concurrent retinal disease which may confound assessment

Additional Sub-study Exclusion Criteria:

  • Ocular media opacity or other condition(s) that, in the opinion of the investigators, may preclude imaging.
  • Individuals who, in the opinion of the investigator, are unable to tolerate study procedures or comply with study requirements.
  • Prior or current treatment with intraocular injections for geographic atrophy (e.g., pegcetacoplan [Syfovre] or similar therapies) is not permitted.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Microperimetry, Optical Coherence Tomography, Adaptive Optics

    Imaging procedures may be completed during a single study visit or across two study visits based on participant availability and operational workflow. When procedures occur across two visits, OCT imaging will be performed first to allow WRC review prior to scheduling microperimetry and AOSLO imaging. If all procedures are completed during a single visit, the total visit time is approximately 5-6 hours. If a second study visit is needed, only the remaining study procedures will be completed, so the second visit will be shorter since the initial ophthalmic procedures have already been performed.

    Device: Adaptive Optics Scanning Light Ophthalmoscopy · Device: Microperimetry · Device: Optical Coherence Tomography

Interventions

  • DeviceAdaptive Optics Scanning Light Ophthalmoscopy

    AOSLO imaging offers unprecedented resolution by correcting optical distortions, enabling direct visualization of individual photoreceptors. The procedure takes 60 minutes.

    Also known as: AOSLO

  • DeviceMicroperimetry

    Microperimetry measures retinal sensitivity at specific retinal locations while tracking eye movements, enabling precise correlation with structural changes. The procedure takes up to 45 minutes.

  • DeviceOptical Coherence Tomography

    OCT will be performed using the Heidelberg Spectralis system with a high-resolution scanning protocol. This is a repeat procedure, the first image was obtained in the main study. The procedure takes 5 minutes.

    Also known as: OCT

06

What researchers measure

Primary outcomes

  1. Incidence of Photoreceptors in EZ absent regions

    The aim is to validate the use of AOSLO imaging for OCT-based EZ classifications, directly visualizing photoreceptor mosaics and correlating EZ loss with photoreceptor structure. Semi-automated machine learning algorithms will be used to segment the EZ layer on OCT images and generate en face maps. All algorithm outputs will be reviewed and verified by trained human graders. AOSLO imaging will validate these maps by providing photoreceptor cell counts and qualitative assessments in the same region

    Time frame: up to 6 hours total during one or two study visits

  2. Area of EZ absent regions on AOSLO vs OCT imaging

    The aim is to validate the use of AOSLO imaging for OCT-based EZ classifications, directly visualizing photoreceptor mosaics and correlating EZ loss with photoreceptor structure. Semi-automated machine learning algorithms will be used to segment the EZ layer on OCT images and generate en face maps. All algorithm outputs will be reviewed and verified by trained human graders. Graders will independently measure area of EZ loss from images of each device. The measurements (in mm²) will be compared between the two devices.

    Time frame: up to 6 hours total during one or two study visits

  3. Correlation of Retinal Sensitivity Data with EZ Status

    The aim is to correlate structural metrics (EZ status from OCT and AOSLO) with functional data (microperimetry), establishing EZ loss as a reliable biomarker for vision loss.

    Time frame: up to 6 hours total during one or two study visits

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2026
First posted
Aug 5, 2026
StartEst.
Nov 5, 2026was Sep 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 29, 2026→Nov 5, 2026
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Start date Sep 29, 2026→Nov 5, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07747662
Responsible party
Sponsor
First posted
Aug 5, 2026
Start date
Nov 5, 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Amitha Domalpally, MD, PhD
principal investigator · University of Wisconsin, Madison

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion